MedTrace Logo

Efficacy and Safety of AQX-1125 in Unstable COPD

NCT01954628 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 400

Last updated 2017-06-12

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the effect of 12 weeks of treatment with once daily administration of AQX-1125 compared to placebo in subjects following exacerbations of Chronic Obstructive Pulmonary Disease (COPD) by targeting the SHIP1 (Src Homology 2-containing Inositol-5'-Phosphatase 1) pathway.

Conditions

Interventions

DRUG

AQX-1125

Synthetic SHIP1 activator

DRUG

Placebo

Placebo control

Sponsors & Collaborators

  • Aquinox Pharmaceuticals (Canada) Inc.

    lead INDUSTRY

Principal Investigators

  • Stephen B Shrewsbury, MD · Aquinox Pharmaceuticals (Canada) Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2015-07-31
Completion
2015-12-31

Countries

  • United States
  • Australia
  • Denmark
  • Finland
  • Hungary
  • New Zealand
  • Poland
  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01954628 on ClinicalTrials.gov